Compare Google Inc (GOOG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Novo Nordisk A/S — how do they compare? Google Inc trades at $347.86 (market cap $4.24T), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Google Inc is far larger — about 25.6× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Novo Nordisk A/S for 116 Days on average.
| GOOG | NVO | |
|---|---|---|
Market Cap | $4.24T | $165.31B |
Volume | 13,937,902 | 11,432,838 |
Sector | Media | Health |
52-Week High | $399.06 | $63.98 |
52-Week Low | $237.49 | $35.29 |
Typical Hold Time | 137 Days | 116 Days |
Enterprise Value | $4.13T | $179.56B |
Dividend Yield | 0.26% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $344.86, down 0.72% today, with a bullish technical signal from moving averages and strong support near $342. The company reported robust Q2 2026 EPS of $9.11, beating expectations, with revenue growth accelerating to $402.84B in 2025. Analyst consensus is strongly bullish with an 87% buy rating and a $435.24 price target, though recent news highlights rising capital expenditures and potential free cash flow pressures.
Outlook remains positive driven by AI and cloud expansion, but risks include heightened spending, regulatory scrutiny, and class-action lawsuits. The stock's valuation at a P/E of 17.3 appears reasonable given high profitability margins, positioning it for long-term growth if execution continues.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
